Hilly Paige Shares Key Takeaways from 2025 ESC/EAS Cholesterol Guideline
Hilly Paige, Chief Innovation Officer at the Family Heart Foundation, has shared a post on LinkedIn:
“Great overview by Family Heart Foundation of the new cholesterol guidelines from European Society of Cardiology and European Atherosclerosis Society.
Figure 2 from the 2025 update is superb. Combinations of proven therapies can lower LDL-C by up to 86%! With so many safe and effective therapies available in the toolbox, it is unacceptable that currently <30% of high-risk individuals are achieving their LDL-C goals!
Also, great to see two important LDL-C lowering therapies included in the 2025 update – bempedoic acid from Esperion and evinacumab from Regeneron!
Finally, using supplements to lower your LDL-C? Don’t waste your money.”
Check here for more information.
Stay informed with Hemostasis Today.
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation
-
Nov 8, 2026, 05:34Eugene Bolotin: Thrombosis and Survival in Pancreatic Cancer